DEA-New Jersey Division: Drug Manufacturer to Pay $2.25 Million to Settle Substances Act Allegations
April 12, 2024
April 12, 2024
NEWARK, New Jersey, April 12 -- The U.S. Justice Department's Drug Enforcement Administration's New Jersey Division issued the following news release on April 10, 2024:
A pharmaceutical manufacturer agreed to pay $2.25 million to resolve allegations that it violated the Controlled Substances Act (CSA), DEA New Jersey Field Division Special Agent in Charge Cheryl Ortiz and U.S. Attorney Philip R. Sellinger announced today.
The manufacturer, Novel Laboratories Inc. (Novel . . .
A pharmaceutical manufacturer agreed to pay $2.25 million to resolve allegations that it violated the Controlled Substances Act (CSA), DEA New Jersey Field Division Special Agent in Charge Cheryl Ortiz and U.S. Attorney Philip R. Sellinger announced today.
The manufacturer, Novel Laboratories Inc. (Novel . . .